Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 6.89Sakar Healthcare Ltd. shows a mixed financial picture, marked by exceptional growth and profitability but contrasted by challenges in operational efficiency and short-term cash management. The company relies very little on debt, indicating strong long-term financial stability, and has been expanding its revenues and profits at a very high rate. This suggests a strong market position and successful strategy. However, its ability to cover immediate bills with available assets appears strained. Furthermore, the company is not as effective as it could be in using its assets to generate sales, taking longer to sell inventory and collect payments. The company is heavily reinvesting its earnings back into the business to fuel growth, which means shareholders are not currently receiving dividends. Overall, it's a high-growth, profitable company with some notable operational and liquidity risks.
Health Score : 6.89Sakar Healthcare Ltd. shows a mixed financial picture, marked by exceptional growth and profitability but contrasted by challenges in operational efficiency and short-term cash management. The company relies very little on debt, indicating strong long-term financial stability, and has been expanding its revenues and profits at a very high rate. This suggests a strong market position and successful strategy. However, its ability to cover immediate bills with available assets appears strained. Furthermore, the company is not as effective as it could be in using its assets to generate sales, taking longer to sell inventory and collect payments. The company is heavily reinvesting its earnings back into the business to fuel growth, which means shareholders are not currently receiving dividends. Overall, it's a high-growth, profitable company with some notable operational and liquidity risks.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
64.59
Industry Median
29.61
Small Cap Median
28.01
P/E RATIO
64.59
P/B RATIO
6.06
Industry Median
3.59
Small Cap Median
3.09
P/S RATIO
7.55
Industry Median
3.55
Small Cap Median
2.75
Others
PEG RATIO
2.91
EV/EBITDA RATIO
26.85
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹884.85 as on Aug 25, 2026.
Growth Score : 10.00The company is experiencing a period of outstanding growth. It has demonstrated an excellent ability to increase its sales, operating profits, and net income at a very high rate. This strong performance extends to the growth in its earnings on a per-share basis and the expansion of its asset base. This across-the-board expansion indicates strong market acceptance and a successful business model that is capturing more market share. The future outlook based on these trends appears very positive, pointing towards continued expansion and increasing scale.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 34.74 | 3.91 | 15.04 | 16.34 | 41.57 |
| Operating Profit Growth Rate | 26.09 | 13.79 | 15.15 | 31.58 | 38 |
| Earnings Per Share (EPS) Growth | 30.12 | -24.72 | -19.85 | 48.42 | 71.89 |
| Asset Growth Rate | 50.56 | 25.37 | 15.77 | 6.68 | 15.9 |
| Net Income Growth Rate | 36.36 | -13.33 | -7.69 | 50 | 66.67 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | ACCENTMIC | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | LINCOLN | 7.31 | 14.09 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | KILITCH | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 4 | NGLFINE | 6.98 | 35.99 | Neutral | 73.00 | 67.39 | 48.00 |
| 5 | SAKAR | 6.89 | 64.59 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 6 | MEDICO | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 7 | KOPRAN | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 8 | SMSLIFE | 6.59 | 22.55 | Undervalued | 45.00 | 58.80 | 19.00 |
| 9 | INFINIUM | 6.42 | 31.32 | Neutral | 22.00 | 6.43 | 14.00 |
| 10 | MEDICAMEQ | 5.73 | 33.47 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | ALBERTDAVD | 5.63 | -332.55 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | ZIMLAB | 5.41 | 114.50 | Neutral | 30.00 | 1.11 | 6.00 |
| 13 | REMUS | 5.31 | 29.34 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | INDSWFTLAB | 4.95 | 68.00 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | VENUSREM | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | WANBURY | 4.65 | 28.36 | Neutral | 88.00 | 18.93 | 43.00 |
| 17 | NECLIFE | 3.83 | -0.75 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Quarterly Report⬤5th Feb 26
Quarterly Financial Results Q3 FY 2025-26
BULLISH SENTIMENT
No Stock News Available at This Moment.
Sakar Healthcare Ltd. is an Indian pharmaceutical company primarily engaged in manufacturing and marketing sterile liquid injectables, lyophilized injectables, ophthalmic drops, and solid oral dosage forms. It focuses on critical care and niche therapeutic areas, serving both domestic and international markets with a commitment to quality and innovation.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Sakar Healthcare Ltd's P/E ratio (TTM) is 64.59, compared to the industry median of 29.61 and large cap median of 28.01.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Sakar Healthcare Ltd's P/B ratio is 6.06, compared to the industry median of 3.59 and large cap median of 3.09.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Sakar Healthcare Ltd's P/S ratio is 7.55, compared to the industry median of 3.55 and large cap median of 2.75.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Sakar Healthcare Ltd's PEG ratio is 2.91.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Sakar Healthcare Ltd's EV/EBITDA ratio is 26.85.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Sakar Healthcare Ltd's ROE is 9.26%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Sakar Healthcare Ltd's ROA is 14.35%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Sakar Healthcare Ltd's ROCE is 13%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Sakar Healthcare Ltd's operating margin is 27.38%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Sakar Healthcare Ltd's net margin is 11.90%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Sakar Healthcare Ltd's current ratio is 1.21.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Sakar Healthcare Ltd's debt-to-equity ratio is 0.10.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Sakar Healthcare Ltd's interest coverage ratio is 6.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Sakar Healthcare Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Sakar Healthcare Ltd's EPS is 71.89.
(Source line: "Ratios as of 25 Aug 2026, based on last traded price of ₹884.85. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2004
Headquarters: Ahmedabad, Gujarat
Core Offerings: Sterile Liquid Injections, Lyophilized Injections, Ophthalmic Drops, Solid Oral Dosages, Topical Preparations
Stock Listing: NSE (SAKAR), BSE ({bse})
Promoter: Sanjay S. Shah / Rasesh S. Shah (Promoter Group)
2004: Incorporated as Sakar Healthcare Limited. 2007: Commenced commercial production of sterile liquid injectables, ophthalmic drops, and oral solid dosages. 2013: Established a dedicated oncology products facility. 2017: Expanded capabilities with lyophilized injectables. The company continues to grow its domestic and international presence in niche therapeutic areas.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Formulations | 100% (primarily) | Operating Profit |
Pharmaceutical Formulations: Engages in the manufacturing of a wide range of pharmaceutical formulations including sterile liquid injectables, lyophilized injectables, ophthalmic drops, and solid oral dosage forms.
Therapeutic Focus: Specializes in critical care, anti-infectives, cardiology, pain management, and oncology segments, catering to diverse medical needs.
Manufacturing Facilities: Operates WHO-GMP certified and other internationally compliant manufacturing plants in Ahmedabad, Gujarat, ensuring high-quality production standards.
Domestic & International Markets: Serves both the Indian domestic market and exports products to various regulated and semi-regulated international markets.
Mr. Sanjay S. Shah - Chairman & Managing Director: A seasoned professional with over two decades of experience in the pharmaceutical sector, he has been pivotal in steering the company's growth and strategic direction. Mr. Rasesh S. Shah - Joint Managing Director: With extensive expertise in operations and business development, he plays a crucial role in enhancing the company's manufacturing capabilities and market reach.
No major subsidiaries reported.
Bonus issue (1:1) in November 2023. Stock split (face value from ₹10 to ₹1) in September 2023.
The Sakar Healthcare Ltd share price today is ₹884.85 on NSE (SAKAR), as of 25 Aug 2026.
As of 25 Aug 2026, Sakar Healthcare Ltd share price is ₹884.85, with previous close ₹884.85. Today's range is ₹884.85 to ₹884.85. The 52-week range is ₹884.85 to ₹884.85.
As of today, Sakar Healthcare Ltd's market cap is ₹1,902.43 crore (Small Cap).
Sakar Healthcare Ltd's current P/E ratio is 64.59, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 38.
Sakar Healthcare Ltd's current P/B ratio is 6.06.
Sakar Healthcare Ltd's current dividend yield is N/A. Last dividend of ₹0.10 per share was declared on 29-May-2024.
Sakar Healthcare Ltd's EPS (TTM) is ₹71.89.
Sakar Healthcare Ltd. is an Indian pharmaceutical company primarily engaged in manufacturing and marketing sterile liquid injectables, lyophilized injectables, ophthalmic drops, and solid oral dosage forms. It focuses on critical care and niche therapeutic areas, serving both domestic and international markets with a commitment to quality and innovation.
Sakar Healthcare Ltd is promoted by Sanjay S. Shah / Rasesh S. Shah (Promoter Group), holding 52.86% as of 25 Aug 2026.
Sakar Healthcare Ltd is listed on NSE (SAKAR) and BSE ({bse}). Its next quarterly results are expected on August 2024.
Adjusted Earnings Per Share (Adjusted EPS)
Receivables Turnover Ratio